Q1 2026 Recap: Nephrology News and Updates
Catch up on nephrology headlines you missed from Q1 2026.
The first quarter of 2026 marked a pivotal period in nephrology, with major regulatory decisions, guideline updates, and late-phase clinical trial readouts reshaping the treatment landscape for chronic kidney disease (CKD) and glomerular disorders. The US Food and Drug Administration advanced multiple high-impact therapies across focal segmental glomerulosclerosis (FSGS), IgA nephropathy (IgAN), and dialysis-related complications, including priority review for atacicept and continued evaluation of sparsentan and oxylanthanum carbonate. At the same time, the Kidney Disease: Improving Global Outcomes released its 2026 Clinical Practice Guideline for anemia in CKD, introducing updated recommendations on iron therapy, erythropoiesis-stimulating agents, and transfusion strategies, with an increased emphasis on individualized, symptom-driven care.